Agnieszka Boesen

Array ( [id] => 11336744 [patent_doc_number] => 20160362500 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-15 [patent_title] => 'Removal of target cells by circulating virus-specific cytotoxic T-cells using MHC class I comprising complexes' [patent_app_type] => utility [patent_app_number] => 15/078962 [patent_app_country] => US [patent_app_date] => 2016-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 30042 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 22 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15078962 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13890053 [patent_doc_number] => 10197573 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-05 [patent_title] => HCV core lipid binding domain monoclonal antibodies [patent_app_type] => utility [patent_app_number] => 15/079013 [patent_app_country] => US [patent_app_date] => 2016-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 42104 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15079013 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11099648 [patent_doc_number] => 20160296618 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-13 [patent_title] => 'EPSTEIN-BARR-VIRUS VACCINE' [patent_app_type] => utility [patent_app_number] => 15/077477 [patent_app_country] => US [patent_app_date] => 2016-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 17357 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15077477 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12239934 [patent_doc_number] => 20180072797 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-15 [patent_title] => 'HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF (V3 ANTIBODIES)' [patent_app_type] => utility [patent_app_number] => 15/559361 [patent_app_country] => US [patent_app_date] => 2016-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 84 [patent_figures_cnt] => 84 [patent_no_of_words] => 18481 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15559361 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15008505 [patent_doc_number] => 10450368 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-22 [patent_title] => HIV-1 neutralizing antibodies and uses thereof (CD4bs antibodies) [patent_app_type] => utility [patent_app_number] => 15/559171 [patent_app_country] => US [patent_app_date] => 2016-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 158 [patent_figures_cnt] => 85 [patent_no_of_words] => 29911 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15559171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12260602 [patent_doc_number] => 20180079798 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-22 [patent_title] => 'TRISPECIFIC BINDING MOLECULES FOR TREATING HBV INFECTION AND ASSOCIATED CONDITIONS' [patent_app_type] => utility [patent_app_number] => 15/558834 [patent_app_country] => US [patent_app_date] => 2016-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 16297 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15558834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11066244 [patent_doc_number] => 20160263208 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-15 [patent_title] => 'INFLUENZA VACCINE FOR SKIN IMMUNIZATION' [patent_app_type] => utility [patent_app_number] => 15/066979 [patent_app_country] => US [patent_app_date] => 2016-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 6903 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15066979 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12909619 [patent_doc_number] => 20180195048 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTION [patent_app_type] => utility [patent_app_number] => 15/550718 [patent_app_country] => US [patent_app_date] => 2016-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37872 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15550718 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12212136 [patent_doc_number] => 09908931 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-06 [patent_title] => 'Anti-hemagglutinin antibodies and methods of use' [patent_app_type] => utility [patent_app_number] => 15/042436 [patent_app_country] => US [patent_app_date] => 2016-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 73 [patent_no_of_words] => 43961 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15042436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12246278 [patent_doc_number] => 09919042 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-20 [patent_title] => 'Influenza virus mutants and uses therefor' [patent_app_type] => utility [patent_app_number] => 15/040277 [patent_app_country] => US [patent_app_date] => 2016-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 77 [patent_no_of_words] => 31770 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15040277 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11040554 [patent_doc_number] => 20160237511 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-18 [patent_title] => 'METHODS FOR DETERMINING VIRAL SENSITIVITY TO VIRAL INHIBITORS' [patent_app_type] => utility [patent_app_number] => 15/040480 [patent_app_country] => US [patent_app_date] => 2016-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 22145 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15040480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12246279 [patent_doc_number] => 09919043 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-20 [patent_title] => 'Influenza virus mutants and uses therefor' [patent_app_type] => utility [patent_app_number] => 15/040705 [patent_app_country] => US [patent_app_date] => 2016-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 77 [patent_no_of_words] => 31759 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15040705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10790103 [patent_doc_number] => 20160136259 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-19 [patent_title] => 'PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS' [patent_app_type] => utility [patent_app_number] => 15/005950 [patent_app_country] => US [patent_app_date] => 2016-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 10650 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15005950 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12117340 [patent_doc_number] => 20180000926 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C VIRUS' [patent_app_type] => utility [patent_app_number] => 15/543216 [patent_app_country] => US [patent_app_date] => 2016-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 39 [patent_no_of_words] => 30096 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15543216 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11964930 [patent_doc_number] => 20170269081 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'MARKER COMBINATIONS FOR DIAGNOSING INFECTIONS AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/531747 [patent_app_country] => US [patent_app_date] => 2015-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 40060 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15531747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10776242 [patent_doc_number] => 20160122397 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-05 [patent_title] => 'REPLIKIN-BASED COMPOUNDS FOR PREVENTION AND TREATMENT OF INFLUENZA AND METHODS OF DIFFERENTIATING INFECTIVITY AND LETHALITY IN INFLUENZA' [patent_app_type] => utility [patent_app_number] => 14/957465 [patent_app_country] => US [patent_app_date] => 2015-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 53064 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14957465 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14454233 [patent_doc_number] => 10323068 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-18 [patent_title] => Hepatitis B virus pre-S1 derived synthetic polypeptides and uses thereof [patent_app_type] => utility [patent_app_number] => 14/945384 [patent_app_country] => US [patent_app_date] => 2015-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 5279 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14945384 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12486765 [patent_doc_number] => 09993526 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-12 [patent_title] => EBV antigen specific T-cell receptor and use thereof [patent_app_type] => utility [patent_app_number] => 14/928762 [patent_app_country] => US [patent_app_date] => 2015-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 6964 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14928762 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11650633 [patent_doc_number] => 20170146534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'METHOD OF DIAGNOSING AND TREATING EPSTEIN BARR VIRUS-BASED MYALGIC ENCEPHALOMYELITIS CHRONIC FATIGUE SYNDROME PATIENTS' [patent_app_type] => utility [patent_app_number] => 14/926989 [patent_app_country] => US [patent_app_date] => 2015-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 10685 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14926989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13142313 [patent_doc_number] => 10088483 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-02 [patent_title] => Subject anti-HCV antibody detection assays employing NS3 capture peptides [patent_app_type] => utility [patent_app_number] => 14/925778 [patent_app_country] => US [patent_app_date] => 2015-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 17 [patent_no_of_words] => 19282 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 304 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14925778 [rel_patent_id] =>[rel_patent_doc_number] =>)